Search for a command to run...
No recent news available for this stock.
Epigral Ltd. stands out as a growth outperformer in the Chemicals sector, exhibiting solid revenue and EPS growth along with competitive profitability metrics. However, compared to its peers, it also shows attractive valuation ratios, making it a compelling investment choice.
Highest Revenue Growth YoY and strong EPS growth, indicating robust business expansion.
Top ROE and ROCE metrics, showing excellent returns on equity and capital.
Highest EPS, reflecting strong earnings performance despite recent revenue declines.